Incidence of adverse events in patients with metastatic breast cancer during use of standard and on/off capecitabine protocols
DOI:
https://doi.org/10.33448/rsd-v11i8.30426Keywords:
Breast neoplasms, Capecitabine, Drug-related side effects and adverse reactions, Pharmaceutical care.Abstract
Capecitabine is a chemotherapy drug widely used in the treatment of metastatic breast cancer. Despite the clinical benefits, adverse events can influence the continuity of therapy. The on/off protocol was designed with the intention of optimizing treatment with capecitabine due to a likely reduction in adverse events. Thus, the aim of the study was to describe the incidence of adverse events during the use of standard and on/off capecitabine protocols. A retrospective cohort study was carried out, in which 221 patients with metastatic breast cancer were analyzed. The sample was divided into groups and subgroups: A - standard; B - on/off; A1 and B1 reduced dose; A2 and B2 full dose. The adverse event with the highest overall incidence (84%) was palmar-plantar erythrodysesthesia syndrome. Most adverse events showed no statistically significant variation in incidence between groups A and B. A higher incidence of adverse events was observed in patients who underwent full dose in both protocols. Regarding severity, most were classified as grade 1 and there was no statistical difference between groups A and B. The study suggests that switching from standard protocol to on/off, with the aim of reducing the incidence and severity of adverse events, does not have a significant impact. Dose reduction is a viable alternative to decrease the incidence of adverse reactions and is clinically relevant in some cases.
References
Buzaid, A. C., Maluf, F. C., Jr., W. N. W., & Barrios, C. H. (2021). Manual de Oncologia Clínica do Brasil. https://mocbrasil.com/
Ciruelos, E. M., Díaz, M. N., Isla, M. D., López, R., Bernabé, R., González, E., & Ponce, S. (2019). Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. Eur J Cancer Care (Engl), 28(6), e13164. https://doi.org/10.1111/ecc.13164
Cohen, P. R. (2017). Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine. Cureus, 9(1), e969. https://doi.org/10.7759/cureus.969
Ferlay, J., M, E., F, L., M, C., L, M., M., P., F, B. (2021). World Cancer Day:Breast cancer overtakes lung cancer in terms of number of new cancer cases worldwide. [PRESS RELEASEN° 294]. https://gco.iarc.fr/today/
Fernández-Ribeiro, F., Olivera-Fernández, R., & Crespo-Diz, C. (2017). Adherence and safety study in patients on treatment with capecitabine. Farmacia Hospitalaria, 41, 204-221.
Gajria, D., Gonzalez, J., Feigin, K., Patil, S., Chen, C., Theodoulou, M., & Traina, T. A. (2012). Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat, 131(1), 111-116. https://doi.org/10.1007/s10549-011-1749-y
Gaudard, A. M. Y. S., Melo, A. C. d., Correr, C. J., Rocha, C. E. d., Galato, D., Junior, D. P. d. L., & Silva, W. B. d. (2016). serviços farmacêuticosdiretamente destinados ao paciente, à família e à comunidade. PROFAR.
Harbeck, N., & Gnant, M. (2017). Breast cancer. Lancet, 389(10074), 1134-1150. https://doi.org/10.1016/s0140-6736(16)31891-8
Hernandez-Aya, L. F., & Ma, C. X. (2016). Chemotherapy principles of managing stage IV breast cancer in the United States. Chin Clin Oncol, 5(3), 42. https://doi.org/10.21037/cco.2016.04.01
Huang, H., Jiang, Z., Wang, T., Zhang, S., Bian, L., Cao, Y., & Song, S. (2012). Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Anticancer Drugs, 23(7), 718-723. https://doi.org/10.1097/CAD.0b013e328351802e
Jolly, T., Williams, G. R., Jones, E., & Muss, H. B. (2012). Treatment of metastatic breast cancer in women aged 65 years and older. Womens Health (Lond), 8(4), 455-469; quiz 470-451. https://doi.org/10.2217/whe.12.18
Kamal, A. H., Camacho, F., Anderson, R., Wei, W., Balkrishnan, R., & Kimmick, G. (2012). Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. Breast Cancer Res Treat, 134(1), 371-378. https://doi.org/10.1007/s10549-012-2037-1
Kobayashi, K., Ito, Y., Matsuura, M., Fukada, I., Horii, R., Takahashi, S., & Hatake, K. (2016). Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. Surg Today, 46(7), 821-826. https://doi.org/10.1007/s00595-015-1252-x
Kwakman, J. J. M., Elshot, Y. S., Punt, C. J. A., & Koopman, M. (2020). Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev, 14(1), 442. https://doi.org/10.4081/oncol.2020.442
Liang, Y., Zhang, H., Song, X., & Yang, Q. (2020). Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol, 60, 14-27. https://doi.org/10.1016/j.semcancer.2019.08.012
Mekdad, S. S., & AlSayed, A. D. (2017). Towards safety of oral anti-cancer agents, the need to educate our pharmacists. Saudi Pharm J, 25(1), 136-140. https://doi.org/10.1016/j.jsps.2015.06.007
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30(2), 239-245. https://doi.org/10.1038/clpt.1981.154
Prichard, D., Norton, C., & Bharucha, A. E. (2016). Management of opioid-induced constipation. Br J Nurs, 25(10), S4-5, s8-11. https://doi.org/10.12968/bjon.2016.25.10.S4
Savarese, D. M. (2017). Common Terminology Criteria for Adverse Events (CTCAE) (Vol. 5).
Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., & Twelves, C. (2003). Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 14(12), 1735-1743. https://doi.org/10.1093/annonc/mdg500
Schilithz, A. O. C., Lima, F. C. d. S. d., Oliveira, J. F. P., Santos, M. d. O., & Rebelo, M. S. (2019). Estimativa | 2020 Incidência de Câncer no Brasil (M. d. Saúde, Ed.).
Schott, S., Schneeweiss, A., Reinhardt, J., Bruckner, T., Domschke, C., Sohn, C., & Eichbaum, M. H. (2011). Acceptance of oral chemotherapy in breast cancer patients - a survey study. BMC Cancer, 11, 129. https://doi.org/10.1186/1471-2407-11-129
Silva, N. L. d., Ribeiro, E., Navarro, J. L., & Zanini, A. C. (2011). Compliance with treatment: related-issues and insights for pharmacist intervention. Brazilian Journal of Pharmaceutical Sciences, 47, 1-12.
Suresh, A., Ganju, A., Morgan, E., Palettas, M., Stephens, J. A., Liu, J., & Williams, N. (2020). Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience. Invest New Drugs, 38(5), 1605-1611. https://doi.org/10.1007/s10637-020-00891-9
Traina, T. A., Theodoulou, M., Feigin, K., Patil, S., Tan, K. L., Edwards, C., & Hudis, C. (2008). Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol, 26(11), 1797-1802. https://doi.org/10.1200/jco.2007.13.8388
Weigelt, B., Peterse, J. L., & van 't Veer, L. J. (2005). Breast cancer metastasis: markers and models. Nat Rev Cancer, 5(8), 591-602. https://doi.org/10.1038/nrc1670
Wells, B., DiPiro, J., Schwighammer, T., & DiPiro, C. (2016). Pharmacotherapy Handbook. In (9 ed., pp. 901): MC Graw Hill Education Artmed.
World Health Organization. (2021). The ATC classification structure and principles. Recuperado de http://www.whocc.no/atc_ddd_index/.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Isabela de Pinho Pestana; Luana do Amaral Brasileiro; Alan Barbosa da Silveira; Livia Costa de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
